ICCCNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31

IMMUCELL CORP /DE/

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026

$10.51−0.24 (-2.23%)

Close on Oct 19, 2026

Market cap: $96.58M
P/E (TTM): 131.4
Dividend yield: –

Fundamental chart

Pick a measure to chart its full history

$27.64MFY2025, +12.8% a year since FY2011

Where these numbers come from

Parsed from the XBRL in Immucell's annual and quarterly filings with the SEC
Per-share figures adjusted for the 1-for-100 reverse split on Jul 25, 1990
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is ICCC.

Revenue growth8.5% · median 12.3%

Gross margin40.3% · median 34.6%

Operating margin12.6% · median -56.3%

Net margin2.6% · median -51.4%

Company	Revenue	Growth
TKNO	$43.70M	+12.3%
ZOMDF	$36.88M	+30.1%
ICCC	$30.68M	+8.5%
BMRA	$4.34M	-11.2%
TRIB	–	–
NNNN	–	–

Company

Next earnings (est.): Nov 12, 2026, after close
Exchange: Nasdaq
Industry: In Vitro & In Vivo Diagnostic Substances
Fiscal year ends: December 31
Employees: 73
Held by institutions: 14.7%
Auditor: Wipfli LLP
SEC CIK: 811641

Advertisement
300 × 250